INTRODUCTION {#s1}
============

Prostate cancer (PCa) has been the first common malignancy bothering western men \[[@R1]\]. Among all the PCa-related death, over 85% patients died from bone metastasis \[[@R2]\]. Currently, the standard first-line treatment of metastatic PCa (mPCa) is androgen deprivation therapy (ADT). Some patients with indolent PCa may survive for decades, however, most patients eventually become resistant to ADT and develop to castration-resistant PCa (CRPC). New bone metastases usually occur in CRPC patients, which indicates a high risk of poor outcome. Besides, CRPC patients need second-line treatment such as abiraterone, chemotherapy and bone-targeted radiotherapy \[[@R3]\]. Some pathological and biochemical tests involved in making prognosis \[[@R4]\], but in fact, no predictors are precise enough for the clinical practice. There is an urgent need for new effective indicators for risk stratification and predicting outcome on treatment decision.

Bone scintigraphy is a widely used examination for patients with mPCa to access metastatic disease burden or treatment effects. However, bone scintigraphy images only provide intensity and size of osseous lesions, which may lead to inaccurate subjective evaluation. To mitigate the shortcoming of bone scintigraphy, Massimo Imbriaco first reported a quantifiable and objective method, bone scan index (BSI), in 1998 \[[@R5]\]. BSI represents the percentage of bone weight affected by tumor to the entire skeleton mass. Initially, the BSI manual calculation was time-consuming and required experienced readers, so it was not introduced into the clinical application. Recently, an automated software package to calculate BSI was commercially available \[[@R6]--[@R7]\]. To date, the prognosis ability of BSI in patients with mPCa has been discussed in several studies, but a few of these studies draw controversial conclusions \[[@R15], [@R17]\]. The aim of this present study was to use a meta-analysis to quantitatively and comprehensively summarize the evidence on the prognostic performance of BSI in patients with mPCa.

RESULTS {#s2}
=======

Study search and characteristics {#s2_1}
--------------------------------

The process of literature selection was shown in a flow diagram (Figure [1](#F1){ref-type="fig"}). A total of 576 studies were initially identified with the keywords used to search the databases. By screening the titles and abstracts, we retrieved 44 potential studies. 30 studies were then excluded after further fully reviewed because they were insufficient of data (27 studies) or consist of same patients (3 studies). Though some studies were in the same institute, the sample patients were at different stage and received different treatment, so we regarded them as different cohorts \[[@R10], [@R16], [@R21]\]. Finally, 14 cohort studies met the inclusion criteria for our meta-analysis.

![Flow chart of literature search and study selection](oncotarget-08-84449-g001){#F1}

The baseline characteristics of the studies were shown in Table [1](#T1){ref-type="table"}. The articles were published from 2010 to 2017, including 1295 patients. Among them, 11 studies \[[@R11]--[@R21]\] used same model of BSI software, EXINI bone (EXINI Diagnostics AB, Lund, Sweden), while the other 3 studies \[[@R8]--[@R10]\] used BONENAVI system (Fujifilm RI Pharma, Co. Ltd., Tokyo, Japan). Overall, the whole 14 studies reported the prognostic ability of BSI in the survival of patients with mPCa.

###### Baseline characteristics of included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                             Country         Duratioin    Sample size   Median age\         Mean serum PSA(ng/ml)   Mean Gleason score   Follow up (months)   Type of PCa              Treatment           HR      95% CI          Cut-off value   Survival outcome   Multivariate analysis   Study quality (NOS score)
                                                                                  (years)                                                                                                                                                                                                               
  ------------------------------------ --------------- ------------ ------------- ------------------- ----------------------- -------------------- -------------------- ------------------------ ------------------- ------- --------------- --------------- ------------------ ----------------------- ---------------------------
  Mitsui et al. 2012 \[[@R8]\]         Japan           2004--2011   42            73 (52--86)         65.3 (0.1--3584.1)      8                    70                   mCRPC                    chemotherapy        3.87    1.24--12.14     3               OS                 yes                     7

  2.67                                 1.211-- 5.886   ∆BSI                                                                                                                                                                                                                                             

  Miyoshi et al. 2016 \[[@R9]\]        Japan           2010--2014   60            72 (55--89)         247.0 (9.7--4206.0)     8.53                 57.8                 hormone-naive PCa        ADT/ chemotherapy   4.676   1.238--17.661   1.90            OS                 yes                     7

  Anand et al. 2016 \[[@R11]\]         Sweden          2012--2014   80            71 (54--84)         46 (3.7--4625)          NR                   40.8                 mCRPC                    ENZ                 NR      NR              ∆BSI NR         OS                 no                      6

  Reza et al. 2014 \[[@R12]\]          Sweden          1996--2010   121           71 (65--77)         72 (20--187)            8                    60                   mPCa                     ADT                 1.26    1.16--1.37      1               OS                 yes                     7

  1.19                                 1.09--1.29      ∆BSI                                                                                                                                                                                                                                             

  Armstrong et al. 2014 \[[@R13]\]     USA             2010--2012   85            75                  NR                      NR                   37                   mCRPC                    tasquinimod         1.64    1.22--2.21      1               OS                 yes                     7

  1.58                                 1.04--2.39      ∆BSI                                                                                                                                                                                                                                             

  2.14                                 NR              ∆BSI         PFS                                                                                                                                                                                                                                 

  Lindgren et al. 2017 \[[@R14]\]      Sweden          2009--2012   48            73 (53--92)         84 (4--5740)            8                    60                   NR                       NR                  1.26    1.13--1.41      0.39            OS                 no                      6

  Meirelles et al. 2010 \[[@R15]\]     USA             1997--2000   43            68 (47--86)         NR                      NR                   60                   mPCa & mCRPC             NR                  1.54    0.63--3.74      1.27            OS                 yes                     7

  Reza et al. 2016(1) \[[@R16]\]       Sweden          2011--2014   104           71 (66--75)         77 (20--180)            NR                   36                   mCRPC                    AA                  1.1     1.009--1.232    ∆BSI            OS                 yes                     7

  Alva et al. 2017 \[[@R17]\]          USA             2013--2014   65            71.8 (46.1--92.2)   NR                      8                    18                   mCRPC                    radium-223          1.01    0.85--1.20      5               OS                 no                      6

  Miyoshi et al. 2016 (2) \[[@R10]\]   Japan           2012--2016   40            75.5 (56.7--86.5)   26.4 (1.8--4645.0)      NR                   36                   mCRPC                    AA/ENZ              1.20    0.31--4.70      1               OS                 Yes                     7

  8.97                                 1.65--48.79     ∆BSI                                                                                                                                                                                                                                             

  Poulsen et al. 2015 \[[@R18]\]       Denmark         until 2013   88            72 (52--92)         73 (4--5740)            7.7                  49                   hormone-sensitive mPCa   ADT                 1.34    1.07--1.67      1               CSS                yes                     7

  Ulmert et al. 2012 \[[@R19]\]        USA             until 2006   384           69 (65--73)         16.8 (8.5--49.4)        7                    120                  PCa & mCRPC              NR                  2.055   1.572--2.687    1               CSS                no                      6

  Dennis et al. 2012 \[[@R20]\]        USA             1997--2005   88            68 (44--83)         95.95 (0.52--2282.15)   8                    6                    mCRPC                    chemotherapy        2.226   1.716--2.736    ∆BSI            PSA-RS             yes                     7

  Reza et al. 2016 (2) \[[@R21]\]      Sweden          2011--2013   47            68 (50--82)         83.1 (4--1294)          NR                   30                   mCRPC                    ODM-201             4.27    0.84--21.6      1               PSA-RS             no                      6

  2.66                                 1.03--6.84      ∆BSI         PFS                                                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported ; ENZ: Enzalutamide ; AA: Abiraterone Acetate; ADT: Androgen deprivation therapy; ΔBSI: BSI change on treatment; OS: Overall Survival; CSS: Cancer specific survival; PFS: Progression free survival; PSA-RS: Prostate specific antigen biochemical recurrence survival.

Quality assessment {#s2_2}
------------------

While there was small variation in the methodological quality of included studies, all 14 included studies were judged as moderate to relative high quality according to the Newcastle--Ottawa Quality Assessment Scale (NOS) assessment tool, with scores from 6 (5 studies) to 7 (9 studies, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

BSI and survival of mPCa {#s2_3}
------------------------

As displayed in Figure [2A](#F2){ref-type="fig"}, the forest plot showed high baseline BSI was significantly associated with poor overall survival (OS). The pooled HR was 1.29 (95% confidence interval \[CI\]: 1.12--1.48, *P* \< 0.001) from 8 studies. Considering the high heterogeneity (*I^2^* = 58.6%, *P* = 0.018 ), we used random-effect model to pool the above variables.

![Forest plot of pooled HRs of baseline BSI in predicting OS (**A**), CSS (**C**), PSA response survival (**D**) and ΔBSI in predicting OS (**B**).](oncotarget-08-84449-g002){#F2}

Elevated BSI change on treatment (ΔBSI) was also correlated with poor OS, with a pooled HR of 1.27 (95% CI: 1.06--1.53, *P* \< 0.001) from 5 studies (Figure [2B](#F2){ref-type="fig"}).

Furthermore, baseline BSI was also prominently related to cancer specific survival (CSS) and prostate specific antigen biochemical recurrence survival (PSA-RS). The pooled HR were 1.65 (95% CI: 1.08--2.51, *P* = 0.019, Figure [2C](#F2){ref-type="fig"}) and 2.26 (95% CI: 1.79--2.84, *P* \< 0.001, Figure [2D](#F2){ref-type="fig"}), respectively.

There were 7 studies providing concordance index (C-index) of BSI on OS and 2 on CSS (Table [2](#T2){ref-type="table"}). We calculated ΔC-index, which represented the improvement of efficacy by adding BSI into the baseline predicting models. As clearly showed in Figure [3](#F3){ref-type="fig"}, BSI could increase the predicting ability of OS and CSS in mPCa (all ΔC-indices were greater than zero).

###### C-indices of predicting models with or without BSI

  Study ID                  C-index (95% CI) including BSI   Baseline c-index       ΔC-index   Survival outcome
  ------------------------- -------------------------------- ---------------------- ---------- ------------------
  Reza et al. 2014          0.83                             0.77                   0.06       OS
  Anand et al. 2016         0.72                             0.67                   0.05       OS
  Miyoshi et al. 2016       0.811                            0.751                  0.06       OS
  Mitsui et al. 2012        0.66                             0.621                  0.039      OS
  Miyoshi et al. 2016 (2)   0.792                            0.721                  0.071      OS
  Lindgren et al. 2017      0.68                             NR                                OS
  Reza et al. 2016 (1)      0.661                            NR                                OS
  Poulsen et al. 2015       0.95 (0.81--1.0)                 0.76 (0.39--1.0)       0.19       CSS
  Ulmert et al. 2012        0.825 (0.754--0.881)             0.768 (0.702--0.837)   0.057      CSS

NR: not reported; OS: Overall Survival; CSS: Cancer specific survival.

![ΔC-index by adding BSI to baseline predicting models](oncotarget-08-84449-g003){#F3}

Subgroup analysis {#s2_4}
-----------------

To deeply explore the relationship between BSI and OS, we performed subgroup analysis based on different types of mPCa, ethnics, cut-off values and sample sizes. The results were summarized in Table [3](#T3){ref-type="table"}, with corresponding forest plots in Figure [4](#F4){ref-type="fig"}.

###### Summary of the subgroup analysis results of BSI and OS

  Variable      Number of studies   Number of patients   Model   Outcome (OS)           Heterogeneity          
  ------------- ------------------- -------------------- ------- ---------------------- --------------- ------ -------
  PCa type                                                                                                     
  mPCa          3                   224                  F       1.269 (1.168--1.378)   \< 0.001        48.8   0.142
  mCRPC         5                   336                  R       1.230 (0.985--1.536)   0.067           67.7   0.015
  Ethnicity                                                                                                    
  Asian         3                   142                  F       2.558 (1.393--4.698)   0.002           0      0.369
  Non-Asian     6                   466                  R       1.205 (1.090--1.332)   \< 0.001        62.6   0.020
  BSI cut-off                                                                                                  
  \> 1          4                   210                  R       1.094 (0.928--1.289)   0.285           72.4   0.012
  ≤ 1           4                   294                  F       1.276 (1.196--1.361)   \< 0.001        0      0.409
  Sample size                                                                                                  
  \> 80         3                   310                  R       1.248 (1.071--1.453)   0.004           76.3   0.015
  \< 80         6                   298                  R       1.309 (1.015--1.688)   0.038           61.0   0.025

F: fixed-effects model; R: random-effects model.

![Subgroup analysis on baseline BSI and OS in patients with mPCa (**A**), mCRPC (**B**) ; Asians (**C**), non-Asians (**D**) ; cut-off value \> 1 (**E**), cut-off value ≤ 1 (**F**) and sample size \> 80 (**G**), sample size \< 80 (**H**).](oncotarget-08-84449-g004){#F4}

Sensitivity analysis {#s2_5}
--------------------

In order to gauge the stability of the results, we conducted sensitivity analysis by removing one study in sequence to see if a single study could have significant impact on the pooled HRs for OS. The results were not significantly altered by removing anyone of the included studies (Figure [5](#F5){ref-type="fig"}).

![Sensitivity analysis of included studies](oncotarget-08-84449-g005){#F5}

Publication bias {#s2_6}
----------------

The funnel plot revealed no significant publication bias in the meta-analysis of baseline BSI and OS (Figure [6A](#F6){ref-type="fig"}, Egger\'s test: *P* value = 0.2 ; Begg\'s test: *P* value = 0.386). Moreover, there was also no potential publication bias on ΔBSI and OS in patients with mPCa (Figure [6B](#F6){ref-type="fig"}, Egger\'s test: *P* value = 0.488 ; Begg\'s test: *P* value = 0.806).

![Funnel plot of Egger\'s test](oncotarget-08-84449-g006){#F6}

DISCUSSION {#s3}
==========

Currently, no standard quantitative imaging biomarkers are available to monitor the clinical changes during treatment in patients with mPCa. Positron emission tomography (PET) has higher sensitivity than plain film, but the results are also not quantitative. Besides, the PET\'s cost is significantly higher than bone scan's, thus not easy to be popularized in the primary hospitals \[[@R22]\]. According to the Food and Drug Administration, a clinical validating biomarker should be measured reproducibly and consistently \[[@R23]\] , while automated BSI showed great potential in mPCa prognosis.

In this meta-analysis, based on the existing data from 14 included studies, the pooled results demonstrated that high baseline BSI indicated unfavorable poor OS, CSS and PSA-RS survival among mPCa patients. Elevated ΔBSI was significantly related to poor OS, which meant the potential feature on treatment monitoring. Given that BSI were acquired at different phases, we could tell if bone metastasis became progressive or stayed indolent, in that progression free survival (PFS) was predictive of OS in men with CRPC \[[@R24]\]. However, only 2 study \[[@R12], [@R21]\] explored the relationship between BSI and PFS, and the raw data was not sufficient to conduct meta-analysis on PFS.

Considering the clinical trails included which couldn\'t avoid heterogeneity since they enrolled in mPCa patients with different stages and involved various treatments. We then performed subgroup analysis. BSI showed predictive value in mPCa patients who mainly received androgen deprivation therapy (ADT, HR = 1.269, 95% CI: 1.168--1.378), however, BSI was not significantly associated with OS in mCRPC (HR = 1.230, 95% CI: 0.985--1.536). Among mCRPC group, the treatment still varied from chemotherapy, tasquinimod, enzalutamide to radium-223. Since the lack of studies, we couldn\'t conduct subgroup analysis on each treatment, so this result should be cautiously interpreted. Ethnicity might serve as a major source of heterogeneity, then we found BSI was significantly correlated with poor OS in Asian patients (HR = 2.558, 95% CI: 1.393--4.698, *I^2^* = 0) and non-Asian group (HR = 1.205, 95% CI: 1.090--1.332, *I^2^* = 62.6%). Because the 3 cohorts from Asian used BONENAVI system which were adjusted by large clinical data from Japanese patients \[[@R25]\], there was no obvious heterogeneity. On the contrary, the non-Asian group contained patients from Europe and USA, who were mainly Caucasians with a small portion of African-American, therefore, which might contribute to heterogeneity. From another aspect, our result supported the main result when cut-off value ≤ 1 (HR = 1.276, 95% CI: 1.196--1.361, *I^2^* = 0), since most studies used the 1 as BSI cut-off \[[@R10], [@R12], [@R13], [@R18], [@R19]\]. What\'s more, the result wasn\'t affected by different sample sizes.

To test the performance of a prognostic model, C-index was known as a parameter like area under the summary receiver operating characteristic curve (SROC) \[[@R26]\]. The range of C-index was 0.5--1.0, and higher C-index meant better efficacy of predicting model. In our study, ΔC-indices were calculated and displayed in a graph, which had clearly shown the added value of BSI to traditional models including clinical T stage, PSA and Gleason score.

Though we failed to conduct a meta-analysis on the relation (r) between BSI and PSA owing to insufficient information, BSI was testified correlated with serum PSA change in several studies \[[@R8], [@R11], [@R13], [@R20]\], using different methods such as Kendall\'s tau, Pearson and Spearman tests. However, Poulsen et al. \[[@R27]\] reported that only BSI served as an independent prognostic factor for survival of men with mPCa, PSA and Gleason scores were not.

To the best of our knowledge, this is the first meta-analysis about BSI and prognosis in mPCa. However, there are still several limitations in the present study. First, among the 14 included studies, only 2 studies were separately eligible for CSS or PSA-RS and 7 studies available for ΔC-index analysis. The number of studies was relatively small. Second, although sensitivity analysis supported the stability of our results, the findings should be cautiously interpreted. Heterogeneity among studies was found probably because of relatively small sample sizes and multivariate influence factors in some included studies. Third, we lack the BSI data and other corresponding clinical parameters on different population at present. Large scale statistics about BSI response during different treatment such as chemotherapy and radiotherapy are also insufficient. So further prospective clinical trials with large sample size are required to verify the prognostic value of BSI on mPCa patients in the future.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

This meta-analysis was conducted under the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@R28]\]. A comprehensive literature search for relevant studies in the PubMed, Embase, Web of Science and the Cochrane library was performed through May 19, 2017. The searching strategy consisted of medical subheadings and key words. The main terms were as follows: 'prostate neoplasms \[MeSH\]' or 'castration resistant prostate cancer' or 'bone metastasis' or 'metastatic prostate cancer' and 'bone scan index' or 'BSI' and 'prognosis \[MeSH\]' or 'survival' or 'outcome'. The language of studies, population and sample size were not restricted. We also manually searched the reference lists for additional relevant publications.

STUDY SELECTION {#s5}
===============

Inclusion and exclusion criteria {#s5_1}
--------------------------------

Studies meeting the following criteria were considered eligible: 1. clinical cohort evaluated the prognostic accuracy of BSI in mPCa; 2. studies compared BSI with other prognosis models and reported survival outcomes like OS, CSS, PFS ; 3. reported original C-index or HR with 95%CI or HR could be extracted from sufficient information; 4. articles with the most complete information if there were multiple studies on the same cohort.

The exclusion criteria were: 1. repeated publications; 2. studies reporting on less than 20 patients; 3. experimental laboratory articles, animal studies, letters or review articles.

Assessment of study quality {#s5_2}
---------------------------

Two investigators (D.L. and H.L.) independently reviewed all relevant articles, then judged the methodology quality of potential studies using NOS assessment tool, including selection, comparability and outcome \[[@R29]\]. A study was considered high quality if the NOS score ≥ 7. When disagreements occurred, the two reviewers reached consensus by involving a third author (H.D.).

Data extraction {#s5_3}
---------------

We extracted the following variables from each study: first author\'s name; publication year; study design; country or region of the study; BSI software type (manufacturer); sample size; age, PSA, Gleason score; cut-off value; follow up time, out-come assessment and risk estimates, C-indices and HRs with 95% CI. If the HRs of both univariate and multivariate analysis for the same comparison were available, we only used the latter. If the HR and 95% CI were not displayed directly, they were estimated from Kaplan--Meier curves \[[@R30]\]. If necessary, the corresponding author could be contacted for further information.

Statistical analysis {#s5_4}
--------------------

HRs with 95%CI were pooled using a meta-analysis to access the strength of BSI to survival endpoints. C-indices of baseline models and the models adding BSI were extracted and the difference values, ΔC-index, were calculated. The Cochrane Q test was used to determine the heterogeneity among studies. A *P* value \< 0.10 indicated heterogeneity. I-square (*I^2^*) was also calculated to evaluate heterogeneity. An *I^2^* value \> 50% was considered significant heterogeneity. The fixed-effect model was used to calculate pooled results when no heterogeneity existed among included studies, otherwise, a random-effect model was used. To find reasons of heterogeneity among studies, we conducted subgroup analysis in different types of mPCa, ethnics, cut-off values and sample sizes, respectively. To test the reliability of the main outcomes in our analysis, sensitivity analysis was performed by removing one single study in turn. Egger\'s and Begg\'s tests with funnel plots were used to test publication bias. *P* value \> 0.05 indicated no potential publication bias. Kaplan--Meier curves were read by Engauge Digitizer version 9.8 (<http://markummitchell.github.io/engauge-digitizer/>). We used Stata 12.0 software (Stata Corporation, College Station, TX, USA) to conduct all the statistical analyses. A two-sided *P* value less than 0.05 was considered statistically significant.

CONCLUSIONS {#s6}
===========

Our study demonstrates that BSI may be beneficial as a predictive imaging marker in mPCa prognosis. We deem that ,with the high prognostic value, baseline BSI and ΔBSI may contribute to monitor and treatment in patients with mPCa.
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